Commodore Capital’s Definium Therapeutics DFTX Stock Holding History

Commodore Capital’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$94.1M	Hold	2,000,000	–	–	5.6%	6
2026 Q1	$37.8M	Hold	2,000,000	–	–	2.19%	16
2025 Q4	$26.8M	Sell	2,000,000 -1,225,000	-38%	-$15.2M	1.78%	23
2025 Q3	$38M	Sell	3,225,000 -1,775,000	-36%	-$16.6M	1.86%	20
2025 Q2	$32.5M	Buy	5,000,000 +475,000	+10%	+$3.12M	2.29%	18
2025 Q1	$26.5M	Buy	4,525,000 +216,575	+5%	+$1.55M	1.95%	18
2024 Q4	$30M	Sell	4,308,425 -3,691,575	-46%	-$25.4M	2.2%	16
2024 Q3	$45.5M	Buy	8,000,000 +854,112	+12%	+$5.94M	2.84%	13
2024 Q2	$51.5M	Buy	7,145,888 +1,312,555	+23%	+$11.5M	3.52%	10
2024 Q1	$54.8M	Buy	+5,833,333	New	+$33.3M	3.67%	8

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Commodore Capital's DFTX Position: Q2 2026 in Review

Commodore Capital held its Definium Therapeutics (DFTX) position steady in Q2 2026 at 2,000,000 shares worth $94.1M. The position accounts for 5.6% of the portfolio, ranked #6.

Commodore Capital first reported a position in DFTX in Q1 2024 and has held it in 10 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Commodore Capital held 2,000,000 shares of Definium Therapeutics worth $94.1M as of Q2 2026.
Commodore Capital left its Definium Therapeutics share count unchanged in Q2 2026.
Definium Therapeutics made up 5.6% of Commodore Capital's portfolio in Q2 2026, its #6 holding.
Commodore Capital first reported a position in Definium Therapeutics in Q1 2024 and has held it in 10 quarters since.
362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Commodore Capital's 13F filing for Q2 2026, filed 14 Aug 2026.